Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Eagle’s Eye View: Beta-Blocker vs. Calcium-Channel Blocker in HCMIn this week’s View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment.
- JACC: Asia State-of-the-Art Review Spotlights Role of AI in CV MedicineWith technological advances like artificial intelligence (AI), machine learning and digital health tools moving from concept into clinical practice, a State-of-the-Art Review in JACC: Asia offers a comprehensive look at digital innovation spanning the full spectrum of cardiology from prevention to treatment to research.
- JACC Spotlight Issue Focuses on CV Statistics in USA special JACC spotlight issue supporting the journal’s recent Cardiovascular Statistics 2026 (JACC Stats) report published online earlier this year offers a comprehensive snapshot of cardiovascular health in the U.S. today. The focused issue, which also includes the inaugural report, expands the analysis beyond clinical disease to the broader drivers of cardiovascular health, examining trends […]
- RENOVATE-COMPLEX-PCI: Benefit With Intravascular Imaging Guidance Maintained at 5 YearsIn the multicenter open-label superiority trial, Joo Myung Lee, MD, MPH, PhD, FACC, et al., randomized 1,639 patients (mean age 66; 20% women) with complex coronary artery lesions across 20 hospitals in South Korea 2:1 to either intravascular imaging-guided PCI (n=1,092) or angiography-guided PCI (n=547). Of the overall cohort, 49% presented with stable ischemic heart […]
- ACCEL Lite: Prasugrel Benefits Patients With Diabetes and Multivessel Disease Post-PCI: TUXEDO-2 TrialIn this interview, Sidney C. Smith Jr., MD, MACC and Sripal Bangalore, MD, MHA discuss the TUXEDO-2 Trial.